Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

Journal of Clinical Investigation

Volumn 121, Issue 9, 2011, Pages 3375-3383

  Jones, Simon A ^a   Scheller, Jürgen ^b   Rose John, Stefan ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALD 518; ALX 0061; C 326; CDP 6038; CNT 0136; CNT 0328; FE 301; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; OLOKIZUMAB; REGN 88; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

AUTOIMMUNITY; DISEASE COURSE; DRUG TARGETING; HOMEOSTASIS; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CYTOKINE RECEPTOR GP130; HUMANS; INFLAMMATION; INTERLEUKIN-6; NEOPLASMS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 80052358980     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57158     Document Type: Review

References (125)

1. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5):364-371. (Pubitemid 37328759)
2. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-442. (Pubitemid 46834849)
3. Ivashkiv L.B., Hu X. The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective? Arthritis Rheum. 2003;48(8):2092-2096. (Pubitemid 36959187)
4. Grivennikov S.I., Karin M. Dangerous laison: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11-19.
5. Kishimoto T. IL-6: From its discovery to clinical applications. Int Immunol. 2010;22(5):347-352.
6. Choy E. RADIATE: More treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nat Clin Pract Rheumatol. 2009;5(2):66-67.
7. Kremer J.M., et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895-1905.
8. Melton L., Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol. 2008;26(9):957-959.
9. Yoshida K., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996; 93(1):407-411. (Pubitemid 26041485)
10. Baumann H., Schendel P. Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem. 1991; 266(30):20424-20427. (Pubitemid 21908476)
11. DeChiara T.M., et al. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell. 1995;83(2):313-322.
12. Elson G.C., et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci. 2000;3(9):867-872.
13. Escary J.L., Perreau J., Dumenil D., Ezine S., Brulet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature. 1993;363(6427):361-364. (Pubitemid 23161534)
14. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(pt 1):1-20. (Pubitemid 37046923)
15. Kopf M., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339-342. (Pubitemid 24104268)
16. Pennica D., et al. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem. 1995;270(18):10915-10922.
17. Pflanz S., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172(4):2225-2231. (Pubitemid 38182370)
18. Robb L., Li R., Hartley L., Nandurkar H.H., Koentgen F., Begley C.G. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med. 1998; 4(3):303-308. (Pubitemid 28144088)
19. Stewart C.L. Leukaemia inhibitory factor and the regulation of pre-implantation development of the mammalian embryo. Mol Reprod Dev. 1994; 39(2):233-238. (Pubitemid 24312167)
20. Kallen K-J. The role of transsignalling via the agonistic soluble IL-6 receptor. Biochim Biophys Acta. 2002;1592(3):323-343. (Pubitemid 35291104)
21. Campbell I.K., O'Donnell K., Lawlor K.E., Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001; 107(12):1519-1527. (Pubitemid 32574638)
22. Ji H., et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196(1):77-85. (Pubitemid 34747313)
23. Liu J., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998;4(1):78-83. (Pubitemid 28133083)
24. Ohshima S., et al. Interleukin-6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998;95(14):8222-8226. (Pubitemid 28326094)
25. Alonzi T., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187(4):461-468. (Pubitemid 28093348)
26. Richards H.B., Satoh M., Shaw M., Libert C., Poli V., Reeves W.H. Interleukin 6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998;188(5):985-990. (Pubitemid 28433425)
27. Eugster H.P., Frei K., Kopf M., Lassmann H., Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol. 1998;28(7):2178-2187. (Pubitemid 28321302)
28. Screpanti I., et al. Inactivation of the IL6-gene prevents development of multicentric Castleman's disease in C/EBP&βετα;- deficient mice. J Exp Med. 1996; 184(4):1561-1566. (Pubitemid 26354714)
29. Lattanzio G., et al. Defective development of pristaneoil- induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol. 1997;151(3):689-696. (Pubitemid 27385600)
30. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J. 1994;300(pt 2):281-290. (Pubitemid 24167878)
31. Jones S.A. Directing transition from innate to acquired immunity: Defining a role for IL-6. J Immunol. 2005;175(6):3463-3468. (Pubitemid 41292002)
32. Rose-John S., Scheller J., Elson G., Jones S. Interleukin- 6 biology is coordinated by membrane-bound and soluble receptors: Role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-236. (Pubitemid 44835496)
33. Jones G.W., et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol. 2010;184(4):2130-2139.
34. McFarland-Mancini M.M., et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol. 2010;184(12):7219-7228.
35. Wunderlich F.T., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010;12(3):237-249.
36. Wong P.K., Quinn J.M., Sims N.A., Van Nieuwenhuijze A., Campbell I.K., Wicks I.P. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammationinduced osteoclastogenesis. Arthritis Rheum. 2006; 54(1):158-168. (Pubitemid 43122198)
37. Kalliolias G.D., Zhao B., Triantafyllopoulou A., Park-Min K.H., Ivashkiv L.B. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKLmediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 2010;62(2):402-413.
38. Niedbala W., et al. Interleukin 27 attenuates collagen- induced arthritis. Ann Rheum Dis. 2008; 67(10):1474-1479.
39. Hermann J.A., Hall M.A., Maini R.N., Feldmann M., Brennan F.M. Important immunoregulatory role of interleukin- 11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 1998;41(8):1388-1397. (Pubitemid 28373117)
40. Walmsley M., Butler D.M., Marinova-Mutafchieva L., Feldmann M. An anti-inflammatory role for interleukin- 11 in established murine collagen-induced arthritis. Immunology. 1998;95(1):31-37. (Pubitemid 28410497)
41. Moreland L., et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 2001;3(4):247-252. (Pubitemid 32621964)
42. Sims N.A. gp130 signaling in bone cell biology: Multiple roles revealed by analysis of genetically altered mice. Mol Cell Endocrinol. 2009;310(1-2):30-39.
43. Nakamura K., Nonaka H., Saito H., Tanaka M., Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology. 2004;39(3):635-644. (Pubitemid 38337643)
44. Hams E., et al. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. J Immunol. 2008;181(3):2174-2180.
45. Esashi E., Ito H., Minehata K., Saito S., Morikawa Y., Miyajima A. Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. Eur J Immunol. 2009; 39(6):1664-1670.
46. Matthews V.B., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010;53(11):2431- 2441.
47. Chesnokova V., Melmed S. Neuro-immuno-endocrine modulation of the hypothalamic-pituitaryadrenal (HPA) axis by gp130 signaling molecules. Endocrinology. 2002;143(5):1571-1574. (Pubitemid 34415869)
48. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med. 1989;169(1):333-338.
49. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-189. (Pubitemid 43214587)
50. McKenzie B.S., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27(1):17-23. (Pubitemid 43083560)
51. Roll P., et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255-1264.
52. Kopf M., Bachmann M.F., Marsland B.J. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov. 2010;9(9):703-718.
53. Modur V., et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest. 1997;100(1):158-168. (Pubitemid 27311254)
54. Nowell M.A., et al. Regulation of pre-B cell colonyenhancing factor by STAT-3-dependent interleukin- 6 trans-signaling: Implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54(7):2084-2095. (Pubitemid 44051064)
55. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005;5(7):521-531. (Pubitemid 40961330)
56. Stumhofer J.S., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7(9):937-945. (Pubitemid 44263907)
57. Stumhofer J.S., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol. 2007;8(12):1363-1371. (Pubitemid 350131173)
58. Stumhofer J.S., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol. 2010;11(12):1119-1126.
59. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. Faseb J. 2001;15(1):43-58. (Pubitemid 32061655)
60. Honda M., et al. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol. 1992;148(7):2175-2180.
61. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170(4):1409-1414. (Pubitemid 19250702)
62. Peters M., et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183(4):1399-1406. (Pubitemid 26134283)
63. Jones S., Richards P.J., Scheller J., Rose-John S. IL-6 transsignaling: The in vivo consequences. J Interferon Cytokine Res. 2005;25(5):241-253. (Pubitemid 40664421)
64. Peters M., et al. Soluble IL-6 receptor leads to a paracrine modulation of the hepatic acute phase response in double transgenic mice. J Immunol. 1997; 159(3):1474-1481. (Pubitemid 127484128)
65. Gearing D.P., Cosman D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell. 1991;66(1):9-10.
66. Nishimoto N., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-2632. (Pubitemid 41510733)
67. Kotake S., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88-95. (Pubitemid 26026748)
68. Desgeorges A., et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol. 1997;24(8):1510-1516. (Pubitemid 27320690)
69. Modur V., Li Y., Zimmerman G.A., Prescott S.M., McIntyre T.M. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest. 1997;100(11):2752-2756. (Pubitemid 28007543)
70. Jones S.A., Novick D., Horiuchi S., Yamamoto N., Szalai A.J., Fuller G.M. C-reactive protein: A physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189(3):599-604. (Pubitemid 29187382)
71. Hurst S.M., et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment. Immunity. 2001;14(6):705-714. (Pubitemid 32592418)
72. Marin V., et al. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: An experimental model involving thrombin. J Immunol. 2001;167(6):3435-3442. (Pubitemid 32852589)
73. Marin V., Montero-Julian F.A., Gres S., Bongrand P., Farnarier C., Kaplanski G. Chemoktactic agents induce IL-6Ra shedding from polymorphonuclear cells: Involvement of a metalloprotease of the TNFalpha- converting enzyme (TACE) type. Eur J Immunol. 2002;32(10):2965-2972.
74. McLoughlin R.M., et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol. 2004; 172(9):5676-5683. (Pubitemid 38542071)
75. Chalaris A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils. Blood. 2007;110(6):1748-1755. (Pubitemid 47443884)
76. Atreya R., et al. Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells. Nat Med. 2000;6(5):583-588.
77. Jostock T., et al. Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem. 2001;268(1):160-167. (Pubitemid 32052260)
78. Nowell M.A., et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003;171(6):3202-3209. (Pubitemid 37093546)
79. Nowell M.A., et al. Therapeutic targeting of IL-6 trans-signaling counteracts STAT3 control of the inflammatory infiltrate in experimental arthritis. J Immunol. 2009;182(1):613-622.
80. Becker C., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity. 2004;21(4):491-501. (Pubitemid 39370505)
81. Richards P.J., et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 2006;54(5):1662-1672.
82. Rose-John S., Waetzig G.H., Scheller J., Grotzinger J., Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007;11(5):613-624. (Pubitemid 46730080)
83. Matsumoto S., et al. Essential roles of IL-6 transsignaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitisassociated premalignant cancer in a murine model. J Immunol. 2010;184(3):1543-1551.
84. Lesina M., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456-469.
85. Müllberg J., et al. IL-6-receptor independent stimulation of human gp130 by viral IL-6. J Immunol. 2000;164(9):4672-4677. (Pubitemid 30238067)
86. Fielding C.A., et al. Viral IL-6 blocks neutrophil infiltration during acute inflammation. J Immunol. 2005;175(6):4024-4029. (Pubitemid 41292065)
87. Curnow S.J., et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/ soluble IL-6 receptor trans-signaling. J Immunol. 2004;173(8):5290-5297. (Pubitemid 39387813)
88. Briso E.M., Dienz O., Rincon M. Cutting edge: Soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008; 180(11):7102-7106.
89. Teague T.K., et al. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J Exp Med. 2000;191(6):915-926.
90. + T regulatory cell development and function during allergic airway inflam mation in vivo. J Clin Invest. 2005;115(2):313-325.
91. Dominitzki S., et al. Cutting edge: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol. 2007;179(4):2041-2045.
92. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000;19(21):2607-2611. (Pubitemid 30339216)
93. Welte T., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A. 2003;100(4):1879-1884. (Pubitemid 36254542)
94. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139-1142. (Pubitemid 34496590)
95. Walker J.G., Smith M.D. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005; 32(9):1650-1653. (Pubitemid 41324798)
96. De Hooge A.S., et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosaninduced arthritis: Exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum. 2004;50(6):2014- 2023. (Pubitemid 38725114)
97. Lissilaa R., et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol. 2010; 185(9):5512-5521.
98. Jenkins B.J., et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med. 2005; 11(8):845-852. (Pubitemid 41161116)
99. Fielding C.A., et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol. 2008;181(3):2189-2195.
100. Regis G., Pensa S., Boselli D., Novelli F., Poli V. Ups and downs: The STAT1: STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008;19(4):351-359.
101. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
102. Grivennikov S., et al. IL-6 and STAT3 signaling is required for survival of intestinal epithelial cells and colitis associated cancer. Cancer Cell. 2009; 16(2):103-113.
103. Bollrath J., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91-102.
104. Schiechl G., et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. J Clin Invest. 2011;121(5):1692-1708.
105. Naugler W.E., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121-124. (Pubitemid 47056470)
106. Ernst M., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest. 2008;118(5):1727-1738. (Pubitemid 351632376)
107. Rebouissou S., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457(7226):200-204.
108. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J.Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone- refractory metastatic breast cancer patients. Br J Cancer. 2003;88(11):1721-1726. (Pubitemid 36760416)
109. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer. 2007;110(9):1911-1928. (Pubitemid 350036849)
110. Jackson C.B., Giraud A.S. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol. 2009;24(4):505-507.
111. Kim D.Y., et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 2009;24(4):646-651.
112. Qu P., et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer. 2009; 63(3):341-347.
113. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007;117(2):337-345. (Pubitemid 46203962)
114. Scheller J., Chalaris A., Garbers C., Rose-John S. ADAM17: A molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011; 32(8):380-387.
115. Klein B., Lu Z.Y., Gaillard J.P., Harousseau J.L., Bataille R. Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol. 1992;182:237-244. (Pubitemid 23018887)
116. Lu Z.Y., Brochier J., Wijdenes J., Brailly H., Bataille R., Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol. 1992;22(11):2819-2824.
117. Sato K., et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851-856. (Pubitemid 23077873)
118. Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-3964.
119. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113-118. (Pubitemid 24016522)
120. Yokota S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008; 371(9617):998-1006. (Pubitemid 351389534)
121. Emery P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: Results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann Rheum Dis. 2008;67(11):1516-1523.
122. Jones S.A., Horiuchi S., Novick D., Yamamoto N., Fuller G.M. Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol. 1998;28(11):3514-3522. (Pubitemid 28510762)
123. Barkhausen T., et al. Selective blockade of interleukin- 6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011; 39(6):1407-1413.
124. Raza K., Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):25-36.
125. Stahl E.A., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42(6):508-514.